Keith Valentine Net Worth

The estimated Net Worth of Keith Valentine is at least $10.5 million dollars as of 2 August 2024. Mr. Valentine owns over 39,000 units of SeaSpine Corp stock worth over $783,616 and over the last 20 years he sold SPNE stock worth over $7,849,647. In addition, he makes $1,840,570 as President, Chief Executive Officer et Director at SeaSpine Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Valentine SPNE stock SEC Form 4 insiders trading

Keith has made over 93 trades of the SeaSpine Corp stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 39,000 units of SPNE stock worth $255,450 on 2 August 2024.

The largest trade he's ever made was exercising 71,155 units of SeaSpine Corp stock on 31 December 2019 worth over $678,819. On average, Keith trades about 7,298 units every 50 days since 2004. As of 2 August 2024 he still owns at least 82,140 units of SeaSpine Corp stock.

You can see the complete history of Mr. Valentine stock trades at the bottom of the page.

Keith Valentine biography

Keith C. Valentine serves as President, Chief Executive Officer, Director of the Company. Prior to joining SeaSpine, Mr. Valentine served as President and Chief Operating Officer of NuVasive, Inc. from January 2007 to January 2015 and as President from December 2004 to January 2007, prior to which he served in various senior executive roles in marketing, development and operations since joining NuVasive in 2001. Previously, Mr. Valentine served as Vice President of Marketing at ORATEC Interventions, Inc., a medical device company acquired by Smith & Nephew PLC, and spent eight years in various roles with Medtronic Sofamor Danek including, Vice President of Marketing for the Rods Division and Group Director for the BMP Biologics program, the Interbody Sales Development Effort, and International Sales and Marketing. Mr. Valentine received a B.B.A. in Management and Biomedical Sciences from Western Michigan University.

What is the salary of Keith Valentine?

As the President, Chief Executive Officer et Director of SeaSpine Corp, the total compensation of Keith Valentine at SeaSpine Corp is $1,840,570. There are no executives at SeaSpine Corp getting paid more.

How old is Keith Valentine?

Keith Valentine is 52, he's been the President, Chief Executive Officer et Director of SeaSpine Corp since 2016. There are 10 older and 10 younger executives at SeaSpine Corp. The oldest executive at SeaSpine Holdings Corp is Keith Bradley, 75, who is the Independent Director.

What's Keith Valentine's mailing address?

Keith's mailing address filed with the SEC is C/O ALPHATEC SPINE, INC., 1950 CAMINO VIDA ROBLE, CARLSBAD, CA, 92008.

Insiders trading at SeaSpine Corp

Over the last 9 years, insiders at SeaSpine Corp have traded over $2,659,931 worth of SeaSpine Corp stock and bought 297,805 units worth $3,591,897 . The most active insiders traders include Stuart Essig, Richard E Caruso et Keith Valentine. On average, SeaSpine Corp executives and independent directors trade stock every 39 days with the average trade being worth of $151,762. The most recent stock trade was executed by John J. Winge on 1 January 2023, trading 4,868 units of SPNE stock currently worth $46,441.

What does SeaSpine Corp do?

SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide.

Complete history of Mr. Valentine stock trades at Alphatec Inc, Nuvasive Inc, Orthofix Medical Inc, SeaSpine Corp et SI-BONE Inc

SeaSpine Corp executives and stock owners

SeaSpine Corp executives and other stock owners filed with the SEC include:

• Keith Valentine,
  President, Chief Executive Officer, Director
• Keith C. Valentine,
  Pres, CEO & Director
• John Bostjancic,
  Chief Financial Officer, Senior Vice President, Treasurer
• Tyler Lipschultz,
  Senior Vice President, Orthobiologics and Business Development
• Patrick Keran,
  Vice President, General Counsel, Secretary
• John Winge,
  Vice President of Sales
• John J. Bostjancic,
  Sr. VP, CFO & Treasurer
• Patrick L. Keran,
  Sr. VP, Gen. Counsel & Sec.
• Dr. Beau Standish P.Eng., Ph.D.,
  Pres of Enabling Technologies
• Kimberly Commins-Tzoumakas,
  Independent Director
• Renee Gaeta,
  Independent Director
• Kirtley Stephenson,
  Independent Non-Executive Chairman of the Board
• Stuart Essig,
  Lead Independent Director
• Michael Fekete,
  Independent Director
• Keith Bradley,
  Independent Director
• John Henneman,
  Independent Director
• Dennis Cirino,
  Senior Vice President, Global Spinal Systems
• Hollis Winkler,
  Sr. VP of HR
• Patrick L. Keran J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Dr. Frank Vizesi,
  Chief Scientific Officer
• Shaeffer Bannigan,
  Sr. Director of Product Devel.
• Paul Benny,
  VP, Corp. Controller, Assistant Treasurer & Assistant Sec.
• Dr. Beau Standish Ph.D.,
  Pres of Enabling Technologies
• Dennis L. Cirino,
  Sr. VP of Global Spinal Systems
• Tyler P. Lipschultz,
  Sr. VP of Orthobiologics & Bus. Devel.
• John J. Winge,
  VP of Sales
• Carrie Mendivil,
  Head of Investor Relations
• James M Sullivan,
  Director
• Cheryl R Blanchard,
  Director
• Brian D. Baker,
  VP, Global Operations
• Richard E Caruso,
  10% owner
• Shweta Maniar,
  Director
• Life Sciences Corp Integra ...,
  
• Beau Standish,
  President, Enabling Tech
• Angela Steinway,
  Director